Found: 13
Select item for more details and to access through your institution.
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2697, doi. 10.1007/s13555-023-01016-9
- By:
- Publication type:
- Article
Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 7, p. 2991, doi. 10.1007/s12325-024-02810-3
- By:
- Publication type:
- Article
417 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.037
- By:
- Publication type:
- Article
416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.036
- By:
- Publication type:
- Article
408 Dupilumab treatment in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.029
- By:
- Publication type:
- Article
307 The study design of a trial of dupilumab in adult patients with bullous pemphigoid (BP): LIBERTY-BP ADEPT.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii4, doi. 10.1093/bjd/ljac140.007
- By:
- Publication type:
- Article
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 4, p. 655, doi. 10.1007/s40257-024-00859-y
- By:
- Publication type:
- Article
A Four-Year History of Pruriginous Erythroderma Leading to the Diagnosis of Idiopathic Hypereosinophilic Syndrome.
- Published in:
- Acta Dermato-Venereologica, 2002, v. 82, n. 5, p. 376, doi. 10.1080/000155502320624140
- By:
- Publication type:
- Article
701 - Dupilumab efficacy and safety up to 2 years in children aged 6 months to 5 years with atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.075
- By:
- Publication type:
- Article
Efficacy of dupilumab treatment in atopic hand and foot dermatitis across morphological subtypes: results from a phase 3, randomized, double-blind, placebo-controlled trial.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii60, doi. 10.1093/bjd/ljad498.062
- By:
- Publication type:
- Article
Dupilumab treatment reduces signs in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii55, doi. 10.1093/bjd/ljad498.057
- By:
- Publication type:
- Article
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 8, p. 805, doi. 10.1001/jamadermatol.2024.1536
- By:
- Publication type:
- Article